Why fosfomycin trometamol as first line therapy for uncomplicated UTI

摘要: Uncomplicated urinary tract infection (UTI) is one of the most common conditions requiring diagnostic and therapeutic intervention. The aetiology treatment these infectious diseases have changed little during last years 'antibiotic era'. Escherichia coli prevalent uropathogen (85->90%) aimed at eradicating using shorter regimes that typically may employ a 3-day course with once-a-day dosing selected drug or single dose particular efficacious antibiotic. Antibiotic resistance to commonly used agents, such as trimethoprim ampicillin, often now exceeds 30-50%, while fosfomycin trometamol, despite many usage, continues be characterized by an extremely low incidence E. resistant strains (about 1%) worldwide. Many factors contributed preserve trometamol antibacterial activity including usage limited infections, very high sustained concentrations rapidly kill bacteria reducing opportunity for mutant selection. In addition there no animal feed contains drug, acquired chromosomal mutations do not spread easily biological cost genetic modifications high. To parameters adds excellent tolerability safety. Although nowadays, microbial limits available resources some drugs can longer recommended reliable because its properties, remains choice eradication uncomplicated UTI.